Učitavanje...
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
Spremljeno u:
| Izdano u: | Clin Kidney J |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://ncbi.nlm.nih.gov/pubmed/34221378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfab062 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|